ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $79 | $65 | $30 | $6 |
| G&A Expenses | $15 | $10 | $6 | $0 |
| SG&A Expenses | $15 | $10 | $6 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $94 | $75 | $37 | $9 |
| Operating Income | -$94 | -$75 | -$37 | -$9 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $14 | $5 | $0 | -$43 |
| Pre-Tax Income | -$80 | -$69 | -$37 | -$52 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80 | -$69 | -$37 | -$52 |
| % Margin | – | – | – | – |
| EPS | -2.56 | -2.17 | -1.1 | -40.44 |
| % Growth | -18% | -97.3% | 97.3% | – |
| EPS Diluted | -2.56 | -2.17 | -1.1 | -40.44 |
| Weighted Avg Shares Out | 31 | 32 | 33 | 1 |
| Weighted Avg Shares Out Dil | 31 | 32 | 33 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $5 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $37 | $0 |
| EBITDA | -$80 | -$75 | $0 | -$52 |
| % Margin | – | – | – | – |